Menu Search
Equities

ImmuPharma PLC

25I:BER

ImmuPharma PLC

Actions
  • Price (EUR)0.0165
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change+1.85%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year ImmuPharma PLC had revenues remain flat at 0.00, though the company grew net income from a loss of 3.81m to a smaller loss of 2.92m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-66.99%
Return on equity-111.20%
Return on investment-111.20%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at ImmuPharma PLC fell by 459.33k. Cash Flow from Financing totalled 722.10k or -- of revenues. In addition the company used 1.36m for operations while cash from investing totalled 188.76k.
Cash flow per share-0.0063
Price/Cash flow per share--
Book value per share0.0065
Tangible book value per share0.0054
More ▼

Balance sheet in GBPView more

ImmuPharma PLC uses little or no debt in its capital structure.
Current ratio1.60
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.